|
|
Commercial Insight: Antithrombotics - Pipeline products to dampen the impact of patent expiries and cost containment initiativesPublished by: Datamonitor Published: Dec. 19, 2006 - 290 Pages Table of ContentsCHAPTER 1 EXECUTIVE SUMMARY Objective of the analysis Datamonitor insight into the antithrombotics market CHAPTER 2 MARKET DEFINITION AND OVERVIEW Market definition for this report Current market situation Antithrombotics market: overview Anticoagulants market Heparins Low molecular weight heparin (LMWH) Parenteral non-heparinoid anticoagulants Oral anticoagulants Antiplatelets market ADP receptor antagonists cAMP enhancing platelet aggregation inhibitors GP 2b/3a inhibitors Other antiplatelets Thrombolytics market National markets Anticoagulants Antiplatelets Thrombolytics Key clinical trials Key clinical trials in the anticoagulant category Lovenox (enoxaparin) Angiomax (bivalirudin) Arixtra (fondaparinux) Key clinical trials in the antiplatelet category Plavix (clopidogrel) Key clinical trials in the thrombolytics category TNK (tenecteplase) Actilyse (tPA, alteplase) CHAPTER 3 COUNTRY MARKET ASSESSMENTS Current and future opportunities and threats in the antithrombotics market Global opportunities and threats Opportunity: increasing patient pool due to changes in demography and lifestyle Threat: cost-conscious pricing and reimbursement environment US US opportunities US threats Japan Japan opportunities Japan threats EU5: opportunities and threats EU5 Opportunities EU5 Threats France: opportunities and threats France opportunities France threats Germany: opportunities and threats Germany opportunities Germany threats Italy: opportunities and threats Italy opportunities Italy threats Spain: opportunities and threats Spain opportunities Spain threats UK: opportunities and threats UK opportunities UK threats Summary of environmental issues affecting the antithrombotic market size CHAPTER 4 FORECAST ANALYSIS Key assumptions and events New products Future outlook on key marketed products Lovenox (enoxaparin) Angiomax (bivalirudin) Arixtra (fondaparinux) Plavix (clopidogrel) GP 2b/3a inhibitors and thrombolytics Generic incursion: patent expiries and marketing exclusivity Limitations of data Forecasts CHAPTER 5 CASE STUDIES: KEY PIPELINE AGENTS Case study A - What commercial potential does the oral anticoagulant market segment harbor? The market opportunity Warfarin’s monitoring requirement and dosing complexity generates an opening in the market for novel oral anticoagulants Oral antiplatelets are unlikely to threaten commercial potential of emerging oral anticoagulants The key competitors in development The commercial potential of oral anticoagulants Patient potential of oral anticoagulants Sales forecast of the two most advanced oral anticoagulants Conclusions Case study B - Will prasugrel capture the antiplatelet market? The market opportunity The unmet need profile of the antiplatelet market indicates opportunities for novel antiplatelets. Commercial potential of prasugrel Drug overview: prasugrel (CS-747) Sales forecast of prasugrel APPENDIX A Bibliography Report methodology Standard units Japanese market data APPENDIX B - MARKET FORECAST DATA US forecasts Japan forecasts France forecasts Germany forecasts Italy forecasts Spain forecasts UK forecasts M5EU forecasts Global forecasts About Datamonitor About Datamonitor Healthcare About the Cardiovascular Disease analysis team Disclaimer AbstractIntroductionThe ageing of the population will result in an increased incidence of coronary artery disease, heart failure and stroke. In addition to these epidemiological forces, the antithrombotics market will be sustained by the forthcoming launch of innovative novel agents whose sales revenue is expected to dampen the commercial impact of generic incursion in blockbuster proceeds. Scope
Demographic trends lead to an increase in the patient population requiring antithrombotic therapy. However, the rising age of the population across all developed regions is increasing the fiscal burden on healthcare payors which are likely to respond by limiting the reimbursement potential of therapies and put pricing pressure on all agents. The highest selling brands in the antidiabetics market are Lovenox (enoxaparin) and Plavix (clopidogrel), but these agents are subject to forthcoming genericization and will thus not contribute to the growth of the antithrombotics market in the medium-to-long term. Pipeline agents are expected to become significant drivers in the market. The antithrombotics market is characterized by pockets of high unmet need and a broad spectrum of similarly efficacious therapeutic strategies. There is regional bias in the choice and popularity of therapeutic strategies driven by cultural reasons as well as infrastructural confines. Reasons to Purchase
Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||